Trans-nasal Complete Nasolabial Cyst Excision

Background: Nasolabial cysts are rare benign epithelial nonodontogenic soft tissue cysts arising in the nasal alar region. Sublabial excision or transnasal endoscopic marsupialization is the standard treatment.

Patients and methods: Between 2019 and 2022, a descriptive retrospective study, including 20 patients who presented with Nasolabial cysts, was conducted.

Study Overview

• Status: Completed
• Conditions: Nasolabial Cyst
• Intervention / Treatment: Procedure: Trans-nasal complete nasalabial cyst excision

Detailed Description

A retrospective study of patients who were presented in the period from 2019 to 2022, with nasolabial cysts. Patients' files were checked for demographic data, clinical presentation, preoperative radiological investigations, histopathology, surgical approach, complications, and outcome.

Technique:

The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.

• Study Type: Observational
• Enrollment (Actual): 20

Contacts and Locations

Study Locations

• Egypt
  • Sohag, Egypt, 82524
    • Mohammed Elrabie Ahmed

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

In upper Egypt In sohag universiy hospital terriary center

Description

Inclusion Criteria:

•Nasolabial cyst

Exclusion Criteria:

• Recurrent cases
• Previous operated

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptoms and clinical sign	The presenting symptoms which made the patient sought medical advice	2 years
Preoperative Computer tomography or soft tissue ultrasound	Radiological description of the lesion	2 years
lining epithelium and inflammatory cell in wall of histopathology	histopathological criteria of the epithelium and cyst wall	2 years
complications and outcome	postoperative complication or recurrence	2 years

Collaborators and Investigators

• Sponsor: Sohag University

Study record dates

Study Major Dates

• Study Start (Actual): March 25, 2022
• Primary Completion (Actual): May 22, 2022
• Study Completion (Actual): July 5, 2022

Study Registration Dates

• First Submitted: August 24, 2022
• First Submitted That Met QC Criteria: September 4, 2022
• First Posted (Actual): September 8, 2022

Study Record Updates

• Last Update Posted (Actual): September 8, 2022
• Last Update Submitted That Met QC Criteria: September 4, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Nasoalveolar - Nasolabial - Klestadt's - Cyst
• Additional Relevant MeSH Terms: Neoplasms; Pathological Conditions, Anatomical; Cysts
• Other Study ID Numbers: SH_1180

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: A retrospective study of patients who were presented in the period from 2019 to 2022, with nasolabial cysts

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No